Interestingly, in a retrospective case series published in 2018, seven patients with advanced PEComa progressing on mTOR inhibitor (sirolimus) were treated with exemestane, an aromatase inhibitor, in combination with everolimus. This evidence concerns the gene CYP19A1 and neoplasm with perivascular epithelioid cell differentiation.